NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (https=) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (https=)
EP (6) EP1880735A3 (https=)
JP (4) JP4846906B2 (https=)
KR (3) KR100642044B1 (https=)
CN (3) CN1191852C (https=)
AR (3) AR022963A1 (https=)
AT (3) ATE459373T1 (https=)
AU (3) AU750788B2 (https=)
BE (1) BE1025464I2 (https=)
BR (4) BRPI0009163B8 (https=)
CA (3) CA2365296A1 (https=)
CY (3) CY1107561T1 (https=)
CZ (3) CZ20013378A3 (https=)
DE (4) DE60043930D1 (https=)
DK (2) DK1163000T3 (https=)
ES (3) ES2275499T3 (https=)
FR (1) FR10C0008I2 (https=)
HK (3) HK1043728B (https=)
HU (4) HU228499B1 (https=)
IL (5) IL145045A0 (https=)
LU (1) LU91652I2 (https=)
MX (1) MXPA01009452A (https=)
MY (2) MY125202A (https=)
NL (1) NL300415I1 (https=)
NO (4) NO330532B1 (https=)
NZ (3) NZ513841A (https=)
PL (3) PL204890B1 (https=)
PT (2) PT1163000E (https=)
SI (2) SI1163000T1 (https=)
TR (3) TR200102739T2 (https=)
TW (3) TWI281403B (https=)
WO (3) WO2000056359A2 (https=)

Families Citing this family (290)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
ATE459373T1 (de) * 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
SI21352A (sl) 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
RU2331435C2 (ru) 2001-12-12 2008-08-20 Š§ŠøрŠ¾Š½ Š”рŠ». Š˜Š¼Š¼ŃƒŠ½ŠøŠ·Š°Ń†Šøя ŠæрŠ¾Ń‚ŠøŠ² chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
JP5116971B2 (ja) * 2002-10-15 2013-01-09 ć‚¤ćƒ³ć‚æćƒ¼ć‚»ćƒ« ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼¢ē¾¤é€£éŽ–ēƒčŒć®ęŽ„ē€å› å­ć‚’ć‚³ćƒ¼ćƒ‰ć™ć‚‹ę øé…ø态ļ½‚ē¾¤é€£éŽ–ēƒčŒć®ęŽ„ē€å› å­ć€ćŠć‚ˆć³ćć®ä½æē”Ø
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer Ī²-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposĆ³b wytwarzania wyodrębnionego polisacharydu, sposĆ³b identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
RU2340627C2 (ru) * 2003-03-13 2008-12-10 Š“Š»Š°ŠŗсŠ¾Š”Š¼ŠøтŠšŠ»Š°Š¹Š½ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶ŠøŠŗŠ°Š»Š· с.Š°. Š”ŠæŠ¾ŃŠ¾Š± Š¾Ń‡ŠøстŠŗŠø Š±Š°ŠŗтŠµŃ€ŠøŠ°Š»ŃŒŠ½Š¾Š³Š¾ цŠøтŠ¾Š»ŠøŠ·ŠøŠ½Š°
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
JP5557415B2 (ja) 2003-06-02 2014-07-23 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ 惐ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ćƒƒć‚Æć‚¹ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ åøē€ć•ć›ćŸćƒˆć‚­ć‚½ć‚¤ćƒ‰ćŠć‚ˆć³å¤šē³–é”žå«ęœ‰ęŠ—åŽŸć‚’å«ć‚€å¾®ē²’å­ć«åŸŗć„ćå…ē–«åŽŸę€§ēµ„ęˆē‰©
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
JP2008508320A (ja) 2004-07-29 2008-03-21 ć‚«ć‚¤ćƒ­ćƒ³ ć‚³ćƒ¼ćƒćƒ¬ć‚¤ć‚·ćƒ§ćƒ³ ļ¼³ļ½”ļ½’ļ½…ļ½ļ½”ļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½‡ļ½ļ½Œļ½ļ½ƒļ½”ļ½‰ļ½ļ½…ć®ć‚ˆć†ćŖć‚°ćƒ©ćƒ é™½ę€§ē“°čŒć«åÆ¾ć™ć‚‹å…ē–«åŽŸę€§ēµ„ęˆē‰©
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ļ¼Œ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ å°æč·Æē—…åŽŸę€§čŒę Ŗē”±ę„ć®ęŠ—åŽŸ
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP3311836A1 (en) * 2005-04-08 2018-04-25 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2605179A1 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
JP5135220B2 (ja) 2005-09-01 2013-02-06 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ ć‚²ćƒ¼ć‚Øćƒ ćƒ™ćƒ¼ćƒćƒ¼ ć‚¢ćƒ³ćƒ‰ ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ć‚«ćƒ¼ć‚²ćƒ¼ 蔀ęø…ē¾¤ļ½ƒé«„č†œē‚ŽčŒć‚’å«ć‚€č¤‡ę•°ćƒÆć‚Æćƒćƒ³ęŽ„ēØ®
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. PartĆ­culas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101515078B1 (ko) 2005-12-22 2015-04-24 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė°±ģ‹ 
MY150105A (en) * 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
KR101711903B1 (ko) * 2006-03-17 2017-03-03 ė” ź±°ė²„ėؼķŠø ģ˜¤ėøŒ ė” ģœ ė‚˜ģ“ķ‹°ė“œ ģŠ¤ķ…Œģ“ģø  ģ˜¤ėøŒ ģ•„ė©”ė¦¬ģ¹“ ģ—ģ¦ˆ ė ˆķ”„ė¦¬ģ  ķ‹°ė“œ ė°”ģ“ ė” ģ„øķ¬ėŸ¬ķ…Œė¦¬ ģ˜¤ėøŒ ė” ė””ķŒŒķŠøėؼķŠø ģ˜¤ėøŒ ķ—¬ģŠ¤ ģ•¤ė“œ ķœ“ėؼ ģ„œė¹„ģ‹œģ¦ˆ ė³µķ•© ė‹¤ź°€ ė©“ģ—­ģ›ģ„± ģ½˜ģ„¬ź²Œģ“ķŠøģ˜ ģ œģ”° ė°©ė²•
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
PE20120262A1 (es) * 2006-03-30 2012-03-30 Glaxosmithkline Biolog Sa Procedimiento para la preparacion de inmunoconjugados que comprenden polisacarido u oligosacarido capsular de s. aureus junto con la proteina portadora
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag ConfĆ³rmeros de adesinas bacterianas
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
DK2074221T3 (da) * 2006-10-10 2010-09-06 Wyeth Llc Forbedrede fremgangsmƄder til separation af streptococcus pneumoniae type 3 polysakkarider
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2690708A1 (en) * 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101621837B1 (ko) 2007-09-12 2016-05-17 ė…øķŒŒė„“ķ‹°ģŠ¤ ģ•„ź²Œ ļ¼§ļ½ļ½“57 ėŒģ—°ė³€ģ“ ķ•­ģ› ė° ļ½‡ļ½ļ½“57 ķ•­ģ²“
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composiĆ§Ć£o antigĆŖnica liofilizada e mĆ©todo para preparaĆ§Ć£o de uma composiĆ§Ć£o imunogĆŖnica
JP2011503104A (ja) 2007-11-09 2011-01-27 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒ†ćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 免ē–«čŖæēƀ化合ē‰©ćŖć‚‰ć³ć«é–¢é€£ēµ„ęˆē‰©ćŠć‚ˆć³ę–¹ę³•
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
EP2252326A4 (en) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd VACCINE COMPOSITIONS
CN102356089B (zh) 2008-02-21 2014-02-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒfHBPå¤šč‚½
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
CN102159540B (zh) 2008-07-21 2015-08-12 åøƒčµ–ę±‰å§†å¦‡å„³åŒ»é™¢ äøŽåˆęˆēš„Ī²-1,6č‘”ē³–čƒŗåÆ”ē³–ē›ø关ēš„ę–¹ę³•å’Œē»„合ē‰©
CA2777837C (en) 2008-10-27 2017-07-11 Novartis Ag Purification method
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptĆ­deo de ch3 da ige.
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US8425922B2 (en) 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
CN103897045A (zh) 2009-01-12 2014-07-02 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ęŠ—é©å…°ę°é˜³ę€§ē»†čŒē–«č‹—äø­ēš„Cna_Bē»“ęž„åŸŸ
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc Ų§Ł„ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ų§Ł„Ł…ŁˆŁ„ŲÆŲ© Ł„Ł„Ł…Ł†Ų§Ų¹Ų© Ł„Ų£Ł†ŲŖŁŠŲ¬ŁŠŁ†Ų§ŲŖ Ų³ŲŖŲ§ŁŁŠŁ„ŁˆŁƒŁˆŁƒŲ³ Ų£ŁˆŲ±ŁŠŲ³
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
JP2013500326A (ja) 2009-07-30 2013-01-07 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ 惐ć‚Æć‚·ćƒ¼ćƒ³ć‚ŗ ć‚Ø惫ć‚Øćƒ«ć‚·ćƒ¼ ęŠ—åŽŸę€§ć‚æć‚¦ćƒšćƒ—ćƒćƒ‰ćŠć‚ˆć³ćć®ä½æē”Ø
CN102596240B (zh) 2009-08-27 2015-02-04 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø åŒ…ę‹¬č„‘č†œē‚ŽēƒčŒfHBPåŗåˆ—ēš„ę‚äŗ¤å¤šč‚½
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
HUE034251T2 (en) 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CA2836153C (en) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
RU2581020C2 (ru) 2009-12-22 2016-04-10 Š”ŠµŠ»Š»Š“ŠµŠŗс Š¢ŠµŃ€Š°ŠæьютŠøŠŗс, Š˜Š½Šŗ. ŠšŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø Š²Š°ŠŗцŠøŠ½
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Ɩzellikleri değiştirilmiş faktƶr h bağlama proteinleri (fhbp) ve bunların kullanım yƶntemi.
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP6027961B2 (ja) 2010-04-07 2016-11-16 ć‚·ć‚§ćƒ³, 惦ć‚ØSHEN, Yue ē²˜č†œćø化合ē‰©ć‚’é€ć‚‹ćŸć‚ć®åŖ’ä½“ć€ćć‚Œć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•ć€åŠć³ć‚·ć‚¹ćƒ†ćƒ 
JP2013530949A (ja) * 2010-05-20 2013-08-01 ć‚Ø惫 ćƒ©ć‚¦ćƒ³ćƒ‰ ć‚øćƒ„ćƒ¼ćƒ³ ęŠ—åŽŸē‰¹ē•°ēš„ļ¼“ļ½’ļ½…ļ½‡äø¦ć³ć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•åŠć³ć‚·ć‚¹ćƒ†ćƒ 
KR20130121699A (ko) 2010-05-28 2013-11-06 ķ…ŒķŠøė¦¬ģŠ¤ ģ˜Øė¼ģø, ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģƒķ˜øģž‘ģš© ķ˜¼ģ„± ė¹„ė™źø° ģ»“ķ“Øķ„° ź²Œģž„ źø°ė°˜źµ¬ģ”°
PL2575870T3 (pl) * 2010-06-04 2017-05-31 Wyeth Llc Preparaty szczepionek
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
KR101711250B1 (ko) 2011-05-06 2017-03-02 ķŽ˜ķŠøė„“ ģ  ė‚˜ė””ģ—ė¹„ģ¹˜ ģ•„ķŒŒė¦° ģ‹œź²”ė¼ ģ†Œė„¤ģ“ ė°•ķ…Œė¦¬ģ•„ģ˜ ģ„øķ¬ģ™ø ė‹¤ė‹¹ė„˜, ģ“ė„¼ ģ œģ”°ķ•˜ėŠ” ė°©ė²•, ģ“ė„¼ ķ•Øģœ ķ•œ ė°±ģ‹  ė° ģ•½ģ œ ģ”°ģ„±ė¬¼
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
RU2636350C2 (ru) 2011-11-07 2017-11-22 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ ŠœŠžŠ›Š•ŠšŠ£Š›Š, Š”ŠžŠ”Š•Š Š–ŠŠ©ŠŠÆ SPR0096 Šø SPR2021
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ é«„č†œē‚ŽčŒļ½ˆå› å­ēµåˆć‚æćƒ³ćƒ‘ć‚Æč³Ŗć®ć‚¢ć‚øćƒ„ćƒćƒ³ćƒˆć•ć‚ŒćŸēµ„ćæåˆć‚ć›
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
JP2015510872A (ja) 2012-03-07 2015-04-13 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼³ļ½”ļ½’ļ½…ļ½ļ½”ļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½Žļ½…ļ½•ļ½ļ½ļ½Žļ½‰ļ½ļ½…ęŠ—åŽŸć®å¢—å¼·ć•ć‚ŒćŸč£½å‰¤
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
RU2727476C2 (ru) 2012-04-26 2020-07-21 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ ŠŠ½Ń‚ŠøŠ³ŠµŠ½Ń‹ Šø Š°Š½Ń‚ŠøŠ³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø
RU2737765C2 (ru) 2012-05-04 2020-12-02 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. ŠŸŃ€Š¾ŃŃ‚Š°Ń‚Š¾Š°ŃŃŠ¾Ń†ŠøŠøрŠ¾Š²Š°Š½Š½Ń‹Šµ Š°Š½Ń‚ŠøŠ³ŠµŠ½Ń‹ Šø ŠøŠ¼Š¼ŃƒŠ½Š¾Ń‚ŠµŃ€Š°ŠæŠµŠ²Ń‚ŠøчŠµŃŠŗŠøŠµ схŠµŠ¼Ń‹ Š½Š° Š¾ŃŠ½Š¾Š²Šµ Š²Š°ŠŗцŠøŠ½
RU2014151567A (ru) 2012-05-22 2016-07-10 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ ŠšŠ¾Š½ŃŠŃŽŠ³Š°Ń‚ Š¼ŠµŠ½ŠøŠ½Š³Š¾ŠŗŠ¾ŠŗŠŗŠ° сŠµŃ€Š¾Š³Ń€ŃƒŠæŠæы х
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
JP6324961B2 (ja) 2012-09-06 2018-05-16 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ 蔀ęø…ē¾¤ļ½‚é«„č†œē‚ŽčŒćØļ½„ļ¼ļ½”ļ¼ļ½ćØ恮ēµ„ćæåˆć‚ć›ćƒÆć‚Æćƒćƒ³
RU2015106791A (ru) 2012-10-03 2016-11-20 Š“Š»ŃŠŗсŠ¾ŃŠ¼ŠøтŠøŠŗŠ»Š°Š¹Š½ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶ŠøŠŗŠ°Š»Š· Š”Š° Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø
EP2906239A1 (en) 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
EA201590491A1 (ru) * 2012-10-17 2016-01-29 Š“Š»Š°ŠŗсŠ¾ŃŠ¼ŠøтŠŗŠ»Š°Š¹Š½ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶ŠøŠŗŠ°Š»Ń Š”.Š. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Š°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberaĆ§Ć£o intradĆ©rmica de composiƧƵes imunolĆ³gicas compreendendo agonistas do receptor do tipo toll
CA2911826C (en) 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
JP2016520077A (ja) 2013-05-15 2016-07-11 悶 ć‚¬ćƒćƒŠćƒ¼ć‚ŗ ć‚Ŗ惖 悶 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ć‚¢ćƒ«ćƒćƒ¼ć‚æ ļ¼„ļ¼‘ļ½…ļ¼’ļ½ˆļ½ƒļ½–ćƒÆć‚Æćƒćƒ³åŠć³ä½æē”Øę–¹ę³•
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
RU2662968C2 (ru) 2013-09-08 2018-07-31 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Š°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя ŠæрŠ¾Ń‚ŠøŠ² neisseria meningitidis (Š²Š°Ń€ŠøŠ°Š½Ń‚Ń‹)
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112016015835B1 (pt) * 2014-01-21 2023-12-26 Pfizer Inc Processo de preparaĆ§Ć£o de conjugados compreendendo polissacarĆ­deos capsulares de streptococcus pneumoniae
CN110859957B (zh) 2014-01-21 2024-04-12 č¾‰ē‘žå…¬åø 包含ē¼€åˆčšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶ē”Ø途
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
KR20160127104A (ko) 2014-02-28 2016-11-02 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė³€ķ˜•ėœ ģˆ˜ė§‰źµ¬ź·  fhbp ķ“ė¦¬ķŽ©ķ‹°ė“œ
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
KR102761870B1 (ko) 2014-07-23 2025-02-05 ģ¹ ė“œėŸ°ģ¦ˆ ķ•˜ģŠ¤ķ”¼ķ‹€ ģ•¤ė“œ ė¦¬ģØģ¹˜ ģ„¼ķ„° ģ•³ ģ˜¤ķ“ėžœė“œ ģøģž h ź²°ķ•© ė‹Øė°±ģ§ˆ ė³€ģ“ģ²“ ė° ģ“ģ˜ ģ‚¬ģš© ė°©ė²•
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
HUE062499T2 (hu) 2015-01-15 2023-11-28 Pfizer Pneumococcus-vakcinĆ”kban tƶrtĆ©nƵ alkalmazĆ”sra szolgĆ”lĆ³ immunogĆ©n kĆ©szĆ­tmĆ©nyek
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
KR102225282B1 (ko) 2015-07-21 2021-03-10 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ģŗ”ģŠķ˜• ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼, ź·øė„¼ ķ¬ķ•Øķ•˜ėŠ” ķ‚¤ķŠø ė° ź·øģ˜ ģš©ė„
CN107921113A (zh) 2015-08-25 2018-04-17 å·“ęƔ唔Ā·é˜æę ¼ę‹‰ę²ƒå°” 免ē–«č°ƒčŠ‚ē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
EP4491735A3 (en) 2015-10-08 2025-04-16 The Governors of the University of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ č‚ŗē‚Žé€£éŽ–ēƒčŒćƒÆć‚Æćƒćƒ³ć«ćŠć„ć¦ē”Øć„ć‚‹ćŸć‚ć®å…ē–«åŽŸę€§ēµ„ęˆē‰©
EP3383426A1 (en) 2015-12-04 2018-10-10 Dana Farber Cancer Institute, Inc. Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
MX2018008797A (es) 2016-01-19 2018-11-29 Pfizer Vacunas contra el cancer.
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
US11191822B2 (en) * 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Fƶrderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031799A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
CN110022894B (zh) 2016-10-07 2024-01-19 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
WO2018065623A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composiƧƵes imunogĆŖnicas para uso em vacinas pneumococais
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102101879B1 (ko) * 2017-03-15 2020-05-29 ģ£¼ģ‹ķšŒģ‚¬ ģ—˜ģ§€ķ™”ķ•™ ė‹¤ź°€ ķė “źµ¬ź·  ė°±ģ‹  ģ”°ģ„±ė¬¼
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2018227177A1 (en) 2017-06-10 2018-12-13 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3641808A1 (en) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
ES3058336T3 (es) 2017-12-06 2026-03-10 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados polisacƔrido-proteƭna de Streptococcus pneumoniae y mƩtodos de uso de los mismos
EP3749357A4 (en) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. ComposiĆ§Ć£o de conjugado polissacarĆ­deo-proteĆ­na pneumocĆ³cico multivalente
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
HRP20230007T1 (hr) 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
US11951162B2 (en) 2018-04-18 2024-04-09 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
EP3824019A1 (en) 2018-07-19 2021-05-26 GlaxoSmithKline Biologicals SA Processes for preparing dried polysaccharides
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN113227125A (zh) 2018-12-12 2021-08-06 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽo-čæžęŽ„ēš„ē³–åŸŗ化ēš„äæ®é„°ēš„č½½ä½“č›‹ē™½
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacƔrido de streptococcus pneumoniae con proteƭna y sus mƩtodos de uso
CN113646438A (zh) * 2019-01-11 2021-11-12 č„æ北大学 åœØ原ę øē”Ÿē‰©ē»†čƒžč£‚č§£ē‰©äø­åˆęˆē”Ÿē‰©ē¼€åˆē‰©ē–«č‹—
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3923982A1 (en) 2019-02-11 2021-12-22 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
BR112021022429A2 (pt) 2019-05-10 2022-03-22 Glaxosmithkline Biologicals Sa ProduĆ§Ć£o de conjugados
BR112021026775A2 (pt) 2019-08-05 2022-05-10 Glaxosmithkline Biologicals Sa Processo para preparar uma composiĆ§Ć£o que compreende um polipeptĆ­deo de proteĆ­na d
AU2020325645A1 (en) 2019-08-05 2022-02-17 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
FI4021487T3 (fi) 2019-11-15 2024-02-06 Enterome S A AntigeenisiƤ peptidejƤ b-solun pahanlaatuisuuden ehkƤisyyn ja hoitoon
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
CN119371566A (zh) 2020-02-21 2025-01-28 č¾‰ē‘žå…¬åø ē³–ē±»ēš„ēŗÆ化
BR112022014555A2 (pt) 2020-02-23 2022-09-20 Pfizer ComposiƧƵes de escherichia coli e mƩtodos das mesmas.
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP7804673B2 (ja) 2020-11-10 2026-01-22 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć•ć›ćŸčŽ¢č†œē³–ęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Ø
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
US20240148849A1 (en) 2021-02-22 2024-05-09 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
JP2024521847A (ja) 2021-05-28 2024-06-04 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆåŒ–čŽ¢č†œē³–ęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Ø
US20250049899A1 (en) 2021-11-18 2025-02-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
AU2023246941A1 (en) 2022-03-31 2024-10-24 Enterome S.A. Antigenic peptides for prevention and treatment of cancer.
CA3256617A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252774A1 (es) 2023-03-30 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990006951A1 (en) * 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL107026A0 (en) * 1992-09-16 1993-12-28 Univ Tennessee Res Corp Antigen of hybrid m protein and carrier for group a streptococcal vaccine
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
JP3429313B2 (ja) 1993-05-18 2003-07-22 ć‚Ŗ惏悤ć‚Ŗćƒ»ć‚¹ćƒ†ć‚¤ćƒˆćƒ»ćƒŖć‚µćƒ¼ćƒćƒ»ćƒ•ć‚”ć‚¦ćƒ³ćƒ‡ćƒ¼ć‚·ćƒ§ćƒ³ äø­č€³ē‚ŽćƒÆć‚Æćƒćƒ³
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
CA2218385A1 (en) * 1995-04-17 1996-10-24 Pierre Hauser Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein eļæ½leniļæ½i iļæ½eren aļæ½ļæ½.
EA199800046A1 (ru) 1995-06-07 1998-06-25 Š‘Š°Š¹Š¾ŠŗŠµŠ¼ Š’эŠŗсŠøŠ½Ń Š˜Š½Šŗ. ŠŸŠ¾Š»ŠøŠæŠµŠæтŠøŠ“, ŠæŠ¾ŃŠ»ŠµŠ“Š¾Š²Š°Ń‚ŠµŠ»ŃŒŠ½Š¾ŃŃ‚ŃŒ Š“Š½Šŗ, Š²Š°ŠŗцŠøŠ½Š½Š°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя (Š²Š°Ń€ŠøŠ°Š½Ń‚Ń‹), Š°Š½Ń‚ŠøтŠµŠ»Š¾ ŠøŠ»Šø ŠµŠ³Š¾ фрŠ°Š³Š¼ŠµŠ½Ń‚, Š²Š°ŠŗцŠøŠ½Š°, ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя уŠŗŠ°Š·Š°Š½Š½Ń‹Ń… ŠæŠ¾Š»ŠøŠæŠµŠæтŠøŠ“Š°, ŠæŠ¾ŃŠ»ŠµŠ“Š¾Š²Š°Ń‚ŠµŠ»ŃŒŠ½Š¾ŃŃ‚Šø Š“Š½Šŗ Šø Š°Š½Ń‚ŠøтŠµŠ»Š° ŠøŠ»Šø ŠµŠ³Š¾ фрŠ°Š³Š¼ŠµŠ½Ń‚Š°
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
ES2262177T3 (es) 1996-05-01 2006-11-16 The Rockefeller University Proteinas de union a colina para vacunas frente a neumococos.
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
AU739129B2 (en) 1997-06-03 2001-10-04 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
EP1140157B1 (en) * 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
CZ301445B6 (cs) 2010-03-03
JP2002540075A (ja) 2002-11-26
CN1192798C (zh) 2005-03-16
PT1162999E (pt) 2007-02-28
EP1162999A2 (en) 2001-12-19
CA2365296A1 (en) 2000-09-28
PL355264A1 (en) 2004-04-05
BR0009163A (pt) 2001-12-26
TR200102736T2 (tr) 2002-04-22
NO20014322L (no) 2001-11-14
CN1191852C (zh) 2005-03-09
HUP0200367A2 (en) 2002-05-29
JP2002539273A (ja) 2002-11-19
IL145044A (en) 2007-03-08
WO2000056358A3 (en) 2001-01-04
EP1163000B1 (en) 2008-02-27
CY1107390T1 (el) 2010-07-28
NZ513840A (en) 2004-02-27
DE60038166T2 (de) 2009-03-12
EP1163000A2 (en) 2001-12-19
IL145044A0 (en) 2002-06-30
US20050031646A1 (en) 2005-02-10
NO20014325D0 (no) 2001-09-05
EP2277535A2 (en) 2011-01-26
KR20020000549A (ko) 2002-01-05
HK1043728A1 (en) 2002-09-27
AU750788B2 (en) 2002-07-25
EP1162998B1 (en) 2010-03-03
HUS1500040I1 (hu) 2018-05-28
LU91652I2 (fr) 2010-10-13
WO2000056358A2 (en) 2000-09-28
CY1107561T1 (el) 2013-03-13
US20110217329A1 (en) 2011-09-08
IL145043A0 (en) 2002-06-30
ATE459373T1 (de) 2010-03-15
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
TWI281403B (en) 2007-05-21
HUP0200664A2 (en) 2002-06-29
BRPI0009163B8 (pt) 2021-05-25
CY2009014I1 (el) 2010-07-28
PL355178A1 (en) 2004-04-05
TWI286938B (en) 2007-09-21
DE122009000054I1 (de) 2009-12-31
BR0009154A (pt) 2001-12-26
WO2000056360A2 (en) 2000-09-28
SI1162999T1 (sl) 2007-04-30
FR10C0008I2 (fr) 2012-10-26
DK1162999T3 (da) 2007-03-26
MY125202A (en) 2006-07-31
KR20020000785A (ko) 2002-01-05
US20100119544A1 (en) 2010-05-13
NO20014322D0 (no) 2001-09-05
TWI235064B (en) 2005-07-01
EP1880735A2 (en) 2008-01-23
DE60032120D1 (de) 2007-01-11
NZ513841A (en) 2001-09-28
DE60038166D1 (de) 2008-04-10
MXPA01009452A (es) 2002-08-06
MY125387A (en) 2006-07-31
AR022963A1 (es) 2002-09-04
LU91652I9 (https=) 2019-01-03
US9168313B2 (en) 2015-10-27
BR0009166A (pt) 2001-12-26
BRPI0009163B1 (pt) 2019-04-09
PL204890B1 (pl) 2010-02-26
AU3813600A (en) 2000-10-09
NO20014325L (no) 2001-11-14
SI1163000T1 (sl) 2008-06-30
PL355180A1 (en) 2004-04-05
EP1162999B1 (en) 2006-11-29
US20030147922A1 (en) 2003-08-07
DK1163000T3 (da) 2008-04-28
AU3291900A (en) 2000-10-09
HU228499B1 (en) 2013-03-28
CZ20013379A3 (cs) 2002-03-13
HUP0200373A2 (en) 2002-06-29
KR20020001785A (ko) 2002-01-09
NO330532B1 (no) 2011-05-09
AR022965A1 (es) 2002-09-04
AR022964A1 (es) 2002-09-04
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
JP2002540074A (ja) 2002-11-26
HU229968B1 (hu) 2015-03-30
BE1025464I2 (https=) 2019-03-06
CA2366314A1 (en) 2000-09-28
KR100642044B1 (ko) 2006-11-10
CN1351503A (zh) 2002-05-29
NO2011014I2 (no) 2011-08-30
WO2000056359A2 (en) 2000-09-28
NL300415I1 (nl) 2009-12-01
DE60043930D1 (de) 2010-04-15
EP1162998A2 (en) 2001-12-19
NO2011014I1 (no) 2011-09-19
HK1043728B (en) 2007-06-22
ATE387214T1 (de) 2008-03-15
FR10C0008I1 (fr) 2010-03-26
CN1351501A (zh) 2002-05-29
US20060093626A1 (en) 2006-05-04
NZ513842A (en) 2004-05-28
PL203917B1 (pl) 2009-11-30
NO330736B1 (no) 2011-06-27
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
WO2000056360A3 (en) 2001-01-25
JP5551579B2 (ja) 2014-07-16
HK1043730A1 (zh) 2002-09-27
TR200102739T2 (tr) 2001-12-21
IL145043A (en) 2007-06-17
KR100798212B1 (ko) 2008-01-24
JP2011057713A (ja) 2011-03-24
US8926985B2 (en) 2015-01-06
AU3430700A (en) 2000-10-09
JP4846906B2 (ja) 2011-12-28
AU750913B2 (en) 2002-08-01
CZ303653B6 (cs) 2013-01-30
CY2009014I2 (el) 2010-07-28
ES2339737T3 (es) 2010-05-25
CN1391481A (zh) 2003-01-15
ES2300255T3 (es) 2008-06-16
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
TR200102735T2 (tr) 2002-04-22
AU750762B2 (en) 2002-07-25
NO20014323D0 (no) 2001-09-05
HK1043731B (en) 2009-01-23
IL145045A0 (en) 2002-06-30
HK1043731A1 (en) 2002-09-27
EP2277535A3 (en) 2011-03-09
EP1880735A3 (en) 2008-03-12
WO2000056359A3 (en) 2001-02-01
US20060002961A1 (en) 2006-01-05
CZ20013378A3 (cs) 2002-03-13
CA2366314C (en) 2012-01-10
EP1776962A1 (en) 2007-04-25
ATE346608T1 (de) 2006-12-15
DE60032120T2 (de) 2007-09-20

Similar Documents

Publication Publication Date Title
BE2015C057I2 (https=)
BE2016C007I2 (https=)
BE2015C018I2 (https=)
BE2014C017I2 (https=)
BE2013C051I2 (https=)
BE2013C020I2 (https=)
BE2013C015I2 (https=)
BE2013C001I2 (https=)
BE2012C036I2 (https=)
LU91652I9 (https=)
BE2008C046I2 (https=)
BE2010C011I2 (https=)
JP2002514480A5 (https=)
IN2001KO01233A (https=)
JP2002521141A5 (https=)
BE2008C047I2 (https=)
BE2011C004I2 (https=)
JP2002521591A5 (https=)
JP2002517184A5 (https=)
JP2002519925A5 (https=)
JP2002513244A5 (https=)
JP2002506962A5 (https=)
JP2002521163A5 (https=)
JP2002513606A5 (https=)
JP2002502016A5 (https=)